跳至主要内容
临床试验/ISRCTN12149022
ISRCTN12149022已完成未知

Effect of food on levothyroxine absorption following a single oral dose of 600 µg in healthy women: an randomised open-label pilot study

IBSA Institut Biochimique SA0 个研究点目标入组 40 人开始时间: 2015年1月30日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Signed written informed consent before inclusion in the study
  • 2. Age 18–50 years old
  • 3. Body-mass index: 18.5–27 kg/m2
  • 4. Vital signs: systolic blood pressure 100–139 mmHg, diastolic blood pressure 50–89 mmHg, heart rate 50–90 beats per minute, measured after 5 minutes at rest in the sitting position
  • 5. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and comply with the requirements of the entire study
  • 6. Women of child-bearing potential must be using at least one of the following reliable methods of contraception and must continue up to 30 days after the last investigational medicinal product administration: 6.1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
  • 6.2. Non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
  • 6.3. Male sexual partner who agrees to use a male condom with spermicide
  • 6.4. Sterile sexual partner
  • 6.5. Non-child-bearing potential or in post-menopausal status for at least 1 year
  • 7. All thyroid function tests within normal limits

排除标准

  • 1. Electrocardiogram 12-leads (supine position): clinically significant abnormalities
  • 2. Physical findings: clinically significant abnormal physical findings that could interfere with the objectives of the study
  • 3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
  • 4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
  • 5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular (including active arrhythmia or history of arrhythmia, particularly atrial fibrillation), respiratory, skin, haematological, genitourinary or neurological diseases that may interfere with the aim of the study; history of endocrine abnormalities, particularly thyroid, hypophysis and hypothalamus dysfunction; autoimmune diseases such as Basedow-Graves and Hashimoto morbi; neoplasia
  • 6. Medications, including over the counter drugs and herbal remedies for 2 weeks before the start of the study
  • 7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study; the 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
  • 8. Blood donations for 3 months before this study
  • 9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (more than one drink per day defined according to the USDA Dietary Guidelines 2010), caffeine (more than five cups of coffee or tea per day) or tobacco abuse (at least 10 cigarettes per day)
  • 10. Positive drug test results at screening or day–1
  • 11. Positive alcohol breath test at day –1
  • 12. Abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study
  • 13. Vegetarians
  • 14. Positive or missing pregnancy test at screening or day–1
  • 15. Pregnant or lactating women

研究者

相似试验